[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas-transplant":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100547381","phase-3-letermovir-prevymis-for-cmv-in-kidney-and-pancreas-transplant-recipients-100547381",false,"NCT06407232","Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients","An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+\u002FR-) Kidney and Kidney\u002FPancreas Transplant Recipients","Inclusion Criteria:\n\n* undergone kidney or simultaneous kidney\u002Fpancreas transplant\n* high-risk CMV serostatus (D+\u002FR-) at time of transplant\n* develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)\n* demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening\n* able to provide informed consent to participate\n\nExclusion Criteria:\n\n* contraindication to letermovir or its excipients\n* develop ganciclovir-resistant CMV infection\n* currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent\n* unable or unwilling, in the opinion of the Investigator, to comply with the protocol\n* pregnant or breastfeeding","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney\u002Fpancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.",[26,27,28],"Cytomegalovirus Infections","Kidney Transplant Infection","Pancreas Transplant","RECRUITING","2026-06-09",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":33},"2024-08-08",{"date":37,"type":20},"2027-08",{"name":39,"class":40},"University of Wisconsin, Madison","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":67,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":41},"100615334","long-term-follow-up-of-the-offspring-born-to-mothers-with-a-solid-organ-transplant-transplantlines-next-generation-100615334","NCT07291258","Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation","Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant","Inclusion Criteria:\n\n* Mother with a KTx, LiTx, PTx (including pancreas islet transplantation), HTx or LuTx before pregnancy (including mothers with multiple transplantation types)\n* Age ≥16 years for offspring born to mother with a KTx or LiTx\n\nExclusion Criteria:\n\n* No informed consent\n* Non Dutch or English speaking",true,{"count":51,"type":20},200,"OBSERVATIONAL","Background Pregnancy after all types of solid organ transplantation (SOT) is possible, although these have higher risk of pregnancy complications for mother and child, such as preeclampsia and preterm birth. Thus, the development of the unborn child seems to be affected by the transplant and its consequences such as the immunosuppressive medication use. Worldwide data regarding follow-up after birth is scarce. The very limited existing data existing only in young children are reassuring. However, the investigators hypothesize that there are health risks for the children. Given the side effects of the immunosuppressive medication on patients and limited knowledge from animal studies, the investigators particularly expect cardiovascular effects such as hypertension and kidney damage. These develop over a long time-period and lead late to symptoms.\n\nAims Aim of this study is to gain more insight into the overall health of offspring born after SOT. Primary aim is to assess the cardiovascular health and the presence of kidney disease, and compare these with reference values from the general population or birth cohorts. Secondary aims are the immunological status including the microbiome of the child given the maternal immunosuppressive medication use, and the overall development of the offspring, including qualitative research regarding the quality of life. Third aim is to assess if there are differences in health between offspring born to mothers with a kidney, liver, pancreas (including pancreas islet), heart and lung transplantation (KTx, LiTx, PTx, HTx, LuTx resp.). The investigators also want to establish a biobank for later follow-up research.\n\nStudy design This will be a cross-sectional monocenter cohort study. All offspring ≥16 years of age born after KTx or LiTx and all offspring born at any age after PTx, HTx and LuTx in the Netherlands will be eligible for inclusion. The investigators estimate that there will be about 150(-220) participants. Before the study visit, participants will be asked to complete a questionnaire. Participants will be invited for a one-time study visit consisting of physical tests (including ultrasound of the kidneys and a 24-hour ambulatory blood pressure measurement) and biological sample (urine, blood and feces) collection, including sample collection for biobanking. Information about the growth and development of the offspring and, if present, diseases and medication use will be collected from the medical files of the general practitioner and pharmacy (LSP) and from data from the youth healthcare check-ups. As a control group pseudoanonymized data from the Lifelines cohort will be used.\n\nDeliverables To the best of our knowledge, this will be the first study worldwide that will gather and analyze detailed information about the cardiovascular, kidney and immunological health at a later age (≥16 years) in the offspring born to mothers after KTx, LiTx, PTx, HTx and LuTx. This information will be important for the preconceptional counseling of families with a pregnancy wish after transplantation and thereby contribute to the health of women with a SOT. Next to that, find adverse effects of the pregnancy after transplantation on the offspring are found, the investigators expect there will be modifiable factors and\u002For early screening\u002Finterventions that can reduce these risks and thereby contribute to the health of the offspring.",[55,56,57,58,59,28,60,61,62,63,64,65,66],"Solid Organ Transplantation","Pregnancy","Long-term Follow-up","Kidney Transplant","Liver Transplant","Heart Transplantation","Lung Transplantation","Offspring, Adult","Children","Cardiovascular Abnormalities","Kidney Disease","Quality of Life",[68,56,69,70,71,72,73,74,75,76],"Solid organ transplantation","Offspring","Long-term follow-up","kidney transplantation","liver transplantation","pancreas transplantation","pancreas islet transplantation","Heart transplantation","lung transplantation","2025-12-04",{"date":79,"type":33},"2025-12-18",{"date":81,"type":33},"2025-10-15",{"date":83,"type":20},"2028-06",{"name":85,"class":40},"University Medical Center Groningen"]